FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

Conclusions
No differences in mPFS were found between the FCGR polymorphisms HH and the others and VV versus the others in KRAS-WT mCRC patients refractory to irinotecan, oxaliplatin and 5-fluorouracil treated with cetuximab. We cannot confirm the effects of other IgG1 antibodies, which may be weaker than previously suggested. Other markers may be needed to study the actual host antibody response to cetuximab.

Source: Gut - May 8, 2015 Category: Gastroenterology Authors: Geva, R., Vecchione, L., Kalogeras, K. T., Jensen, B. V., Lenz, H.-J., Yoshino, T., Paez, D., Montagut, C., Souglakos, J., Cappuzzo, F., Cervantes, A., Frattini, M., Fountzilas, G., Johansen, J. S., Hogdall, E. V., Zhang, W., Yang, D., Yamazaki, K., Nishi Tags: Colon cancer Source Type: research